Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced positive topline results from its Phase 3 Casppian clinical trial evaluating the efficacy and safety of FP-001 42 mg (leuprolide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback